347 related articles for article (PubMed ID: 29730815)
1. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
Hwang K; Koh EJ; Choi EJ; Kang TH; Han JH; Choe G; Park SH; Yearley JH; Annamalai L; Blumenschein W; Sathe M; McClanahan T; Jung H; Wang KC; Kim SK; Kim CY
J Neurooncol; 2018 Sep; 139(2):281-291. PubMed ID: 29730815
[TBL] [Abstract][Full Text] [Related]
2. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM
Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470
[TBL] [Abstract][Full Text] [Related]
3. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
[TBL] [Abstract][Full Text] [Related]
4. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
5. Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy.
Cacciotti C; Fleming A; Ramaswamy V
J Pathol; 2020 Jul; 251(3):249-261. PubMed ID: 32391583
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.
Zhang L; Zhang B; Dou Z; Wu J; Iranmanesh Y; Jiang B; Sun C; Zhang J
Front Immunol; 2021; 12():582594. PubMed ID: 33815356
[No Abstract] [Full Text] [Related]
7. The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.
Wang L; Han S; Yan C; Yang Y; Li Z; Yang Z
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1259-1270. PubMed ID: 33387039
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
9. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Jang BS; Kim IA
Radiother Oncol; 2018 Aug; 128(2):245-253. PubMed ID: 29784449
[TBL] [Abstract][Full Text] [Related]
10. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
11. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
[TBL] [Abstract][Full Text] [Related]
12. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype.
Haberler C; Laggner U; Slavc I; Czech T; Ambros IM; Ambros PF; Budka H; Hainfellner JA
Am J Surg Pathol; 2006 Nov; 30(11):1462-8. PubMed ID: 17063089
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics of atypical teratoid/rhabdoid tumor.
Oka H; Scheithauer BW
Neurol Med Chir (Tokyo); 1999 Jul; 39(7):510-7; discussion 517-8. PubMed ID: 10437379
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
[TBL] [Abstract][Full Text] [Related]
17. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
18. Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort.
Benesch M; Nemes K; Neumayer P; Hasselblatt M; Timmermann B; Bison B; Ebetsberger-Dachs G; Bourdeaut F; Dufour C; Biassoni V; Morales La Madrid A; Entz-Werle N; Laithier V; Quehenberger F; Weis S; Sumerauer D; Siebert R; Bens S; Schneppenheim R; Kool M; Modena P; Fouyssac F; C Frühwald M
Pediatr Blood Cancer; 2020 Jan; 67(1):e28022. PubMed ID: 31571386
[TBL] [Abstract][Full Text] [Related]
19. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
Zhu S; Lv X; Zhang X; Li T; Zang G; Yang N; Wang X; Wu J; Chen W; Liu YJ; Chen J
Int J Cancer; 2019 Jun; 144(11):2867-2879. PubMed ID: 30565657
[TBL] [Abstract][Full Text] [Related]
20. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
